

## List of Tables

<b>Table no.</b>	<b>Content of tables</b>	<b>Page no.</b>
Table 1.1:	Factors that increase the Relative Risk for Breast Cancer	3
Table 1.2:	Breast cancer outcomes in molecular types of breast cancer	8
Table 1.2:	Frequency and outcome of histological types of invasive breast cancer	9
Table 2.1:	Bcl-2 family members	33
Table 2.2:	Bio-molecular markers of breast cancers	34
Table 2.3:	Drugs used for breast cancer treatment	37
Table 2.4:	ZD6474 kinase activity	41
Table 3. 1:	Cell cycle study of breast cancer cells	59
Table 3.1:	Influence of ZD6474 on MDA-MB-231 xenograft tumor growth	63
Table 4.1:	Effect of various drugs on breast cancer cells	84
Table 4.2:	ZD6474 potentiates paclitaxel action on breast cancer cells	86
Table 5. 1:	ZD6474 potentiates UV-B action on breast cancer cells	112
Table 5. 2:	Mitochondrial membrane potential ( $\Delta\Psi_m$ ) of ZD6474 and/or UV-B treated breast cancer cells	117

## List of Figures

<b>Figure no.</b>	<b>Legend</b>	<b>Page no.</b>
Figure 1.1:	Demographic profiles of cancer cases in Indian females	2
Figure 1.2:	Anatomy of female breast	4
Figure 1.3:	Histology of breast carcinoma	5
Figure 1.4:	Dendrogram of breast cancer	8
Figure 1.5:	Receiver Operating Characteristic curves for logistic regression models	10
Figure 1.6:	Overall survival (OS)% of different molecular subtypes of breast cancer patients after receiving post mastectomy radiation therapy	15
Figure 1.7:	Model for the effect of molecular profiling on breast cancer	17
Figure 2.1:	Estrogen receptor and its cross talk signaling with Receptor tyrosine kinase (RTK)	24
Figure 2.2:	Epidermal growth factor receptor and Vascular endothelial growth factor receptor signaling in breast cancer	27
Figure 2.3:	Apoptosis and cross-talk signaling with RTK in breast cancer	32
Figure 2.4:	Chemical structure of ZD6474	40
Figure 3. 1:	Dose-dependent growth inhibitory effects of ZD6474 on breast cancer cell lines	58
Figure 3.2:	ZD6474 induces apoptosis in breast cancer cells	60
Figure 3.3:	ZD6474 inhibits EGFR and VEGFR signaling pathways	61
Figure 3.4:	ZD6474 inhibits anchorage-independent cell proliferation, chemoinvasion and migration	62
Figure 3.5:	Antitumor activity of ZD6474 in MDA-MB-231 human breast carcinoma xenografts	65
Figure 3.6:	<i>In vivo</i> effect of ZD6474 in proliferation, apoptosis and angiogenesis	68
Figure 3.7:	<i>In vivo</i> effect of ZD6474 in EGFR and VEGFR signaling pathways	69
Figure 4.1:	Dose-dependent growth inhibition of breast cancer cells by ZD6474, AEE788, PKI-166 and paclitaxel	84

Figure 4.2: Dose-effect curves of breast cancer cells treated with ZD6474 and/or paclitaxel	86
Figure 4.3: ZD6474 enhances antiproliferative and apoptotic effects of paclitaxel	88
Figure 4.4: ZD6474 modulates paclitaxel action by altering the expression of cell regulatory and apoptotic proteins	89
Figure 4.5: ZD6474 inhibits migration, decreases wound healing and inhibits anchorage-independent growth in breast cancer cells	91
Figure 4.6: ZD6474 suppresses motile cell phenotypes in breast cancer cells	93
Figure 5.1: Effect of radiation on VEGF content in breast cancer cells	111
Figure 5.2: Dose-dependent growth inhibition of breast cancer cells by UV-B radiation in combined with ZD6474	111
Figure 5.3: Photomicrograph of MCF-7 and MDA-MB-468 irradiated with different doses of UV-B and/or ZD6474	113
Figure 5.4: ZD6474 enhances antiproliferative and apoptotic effects of UV-B radiation	114
Figure 5.5: Apoptosis studies of ZD6474 and UV-B irradiated MDA-MB-468 by Confocal Laser Scanning Microscopy (CLSM)	115
Figure 5.6: Loss of mitochondrial potential ( $\Delta\Psi_m$ ) in ZD6474 and UV-B irradiated MDA-MB-468	117
Figure 5.7: Enzyme kinetics of caspase-3/7 using Ac-DEVD-pNA as substrate	119
Figure 5.8: ZD6474 modulates UV-B action by altering the expression of cell regulatory and apoptotic proteins	120
Figure 5.9: ZD6474 inhibits migration and decreases wound healing in breast cancer cells in combination with UV-B	122
Figure 5.10: ZD6474 inhibits secretion of VEGF in breast cancer cells in combination with UV-B	123
Figure 5.11: Effect of ZD647 and UV-B on transcriptional regulation of VEGF	124
Figure 5.12: ZD6474 alters cytoskeleton organization	125
Figure 5.13: Photomicrograph of the surface of breast cancer cell studied	126

under scanning electron microscope (SEM)	
Figure 5.14: ZD6474 inhibits MMP-9 activity in combination with UV-B	127
Figure 6.1: Physicochemical characterization of AuNp and ZD647-AuNp by UV-VIS absorption spectroscopy	141
Figure 6.2: Characterization of the gold nanoparticles using HR-TEM	142
Figure 6.3: Chemical analysis of AuNp and ZD6474-AuNp by using FTIR	143
Figure 6.4: Stability of AuNp	144
Figure 6.5: Size and charge distribution in AuNp and ZD-AuNp	144
Figure 6.6: ZD6474-AuNp enhances the effect of ZD6474 in decreasing cell viability in breast cancer cells	146
Figure 6.7: ZD6474-AuNp enhances the effect of ZD6474 in inducing apoptosis in breast cancer cells	147
Figure 6.8: AuNp is compatible with circulatory RBC	148
Figure 7.1: ZD6474 overcame paclitaxel resistance in paclitaxel resistance MCF-7 (MCF-7/PAC)	158
Figure 7.2: ZD6474 influenced the action of paclitaxel in decreasing cellular protrusions	159
Figure 7.3: Schematic representation of ZD6474 mediated cell proliferation, apoptosis and invasion pathways	160

## CONTENTS

<b>Contents</b>	<b>Page no.</b>
Title page	i
Dedication	ii
Certificate of Approval	iii
Certificate	iv
Declaration	v
Acknowledgement	vi
List of symbols and abbreviations	vii-ix
List of tables	x
List of figures	xi-xiii
Contents	xiv-xvii
Abstract	xviii
<b>Chapter 1: Introduction</b>	<b>1-20</b>
<b>1.1 Breast cancer</b>	<b>2</b>
<b>1.2 Risk factors of breast cancer</b>	<b>3</b>
<b>1.3 Classification of breast cancer</b>	<b>4-8</b>
1.3.1 Histopathological classification	
1.3.2 Molecular classification	
<b>1.4 Clinical outcomes of breast cancer in association with clinical, histopathological and molecular classification</b>	<b>8-11</b>
<b>1.5 Screening and detection of breast cancer</b>	<b>11-12</b>
<b>1.6 Breast Cancer Treatment</b>	<b>12-17</b>
1.6.1 Surgery	
1.6.2 Radiation therapy	
1.6.3 Chemotherapy and molecular targeted-therapy	
<b>References</b>	<b>18-19</b>
<b>Chapter 2: Review of literature</b>	<b>21-48</b>
<b>2.1 Introduction</b>	<b>22-23</b>
<b>2.2 Receptors of breast cancer</b>	<b>23-31</b>
2.2.1 Estrogen receptor	
2.2.2 Epidermal growth factor receptor	
2.2.3 Vascular endothelial growth factor receptor	
<b>2.3 Apoptosis</b>	<b>31-36</b>
2.3.1 Apoptosis regulators	
<b>2.4 Molecular targets and chemotherapeutic drugs</b>	<b>36-41</b>
2.4.1 ZD6474 (Vandetanib; Zactima™)	
<b>2.5 Objective and Scope</b>	<b>41</b>
<b>References</b>	<b>42-47</b>

<b>Chapter 3: ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells</b>	49-74
<b>3.1 Introduction</b>	50-52
<b>3.2 Materials and Methods</b>	52-57
3.2.1 Cell Lines	
3.2.2 Reagents	
3.2.3 Cell viability	
3.2.4 Cell cycle and apoptosis	
3.2.5 DNA laddering	
3.2.6 Western blot analysis of growth regulatory proteins and apoptosis proteins	
3.2.7 Western blot analyses of pEGFR/EGFR, pVEGFR-2/VEGFR-2, pMAPK/MAPK, pAkt/Akt	
3.2.8 Colony formation assays	
3.2.9 Boyden chamber assay	
3.2.10 <i>In vivo</i> xenografts	
3.2.11 Immunohistochemistry (IHC)	
3.2.12 Apoptosis study by Terminal deoxynucleotidyltransferase dUTP nick end labeling (TUNEL)	
<b>3.3 Results</b>	57-64
3.3.1 ZD6474 suppresses the <i>in vitro</i> cell proliferation of breast cancer cells in a dose-dependent manner	
3.3.2 ZD6474 induces cell cycle arrest at the G0-G1 phase	
3.3.3 ZD6474 induces apoptosis in breast cancer cells	
3.3.4 ZD6474 inhibits epidermal growth factor receptor and vascular endothelial growth factor receptor signaling in breast cancer cells	
3.3.5 ZD6474 inhibits colony formation, chemoinvasion and angiogenesis	
3.3.6 Antitumor effect of ZD6474 in nude mice	
3.3.7 ZD6474 blocks epidermal growth factor receptor and vascular endothelial growth factor receptor signaling in breast carcinoma cells growing subcutaneously in nude mice	
<b>3.4 Discussion</b>	64-70
<b>References</b>	71-73
<b>Chapter 4: ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells</b>	75-100
<b>4.1 Introduction</b>	76-78
<b>4.2 Materials and Methods</b>	78-83
4.2.1 Cell Lines	
4.2.2 Reagents	
4.2.3 Evaluation of ZD6474 and/or paclitaxel cytotoxicity	
4.2.4 Combination index (CI) calculations and determination of the potentiation factor (PF)	
4.2.5 Apoptosis measurement by flow-cytometry	
4.2.6 DNA laddering	

4.2.7 Western blot analysis of growth regulatory proteins and apoptosis proteins	
4.2.8 Caspase-3 and caspase-7 activity assays	
4.2.9 Colony formation assays	
4.2.10 <i>In vitro</i> wounding (scratch) assay	
4.2.11 Immunofluorescence Studies	
<b>4.3 Results</b>	83-93
4.3.1 ZD6474 suppresses cell viability of breast cancer cells.	
4.3.2 ZD6474 in combination with paclitaxel cooperatively inhibits growth <i>in vitro</i> .	
4.3.3 ZD6474 inhibits cell proliferation and induces apoptosis in combination with paclitaxel.	
4.3.4 ZD6474 alters cell regulatory proteins and apoptotic proteins when used in combination with paclitaxel	
4.3.5 ZD6474 inhibits colony formation and migration when used in combination with paclitaxel	
4.3.6 ZD6474 in combination with paclitaxel induces cytoskeleton reorganization in breast cancer cells	
<b>4.4 Discussion</b>	94-98
<b>References</b>	99-100
<b>Chapter 5: Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of radiotherapy in breast cancer cells</b>	101-134
<b>5.1 Introduction</b>	102-103
<b>5.2 Materials and Methods</b>	103-110
5.2.1 Cell Lines	
5.2.2 Reagents	
5.2.3 UV-B irradiation	
5.2.4 Evaluation of ZD6474 and/or UV-B irradiation cytotoxicity	
5.2.5 Apoptosis measurement by flow-cytometry	
5.2.6 Measurement of mitochondrial membrane potential ( $\Delta\Psi_m$ )	
5.2.7 Preparation of cytosolic and mitochondrial extracts	
5.2.9 Caspase-3 and caspase-7 activity assays	
5.2.10 <i>In vitro</i> wounding (scratch) assay	
5.2.11 Scanning Electron Microscopy (SEM)	
5.2.12 Immunofluorescence studies	
5.2.13 VEGF quantification	
5.2.14 Zymography	
5.2.15 Plasmid constructs and transient transfections	
<b>5.3 Results</b>	110-127
5.3.1 Radiation (UV-B) suppresses cell viability of breast cancer cells.	
5.3.2 ZD6474 in combination with UV-B cooperatively inhibits growth <i>in vitro</i> .	
5.3.3 ZD6474 inhibits cell proliferation and induces apoptosis in combination with UV-B	
5.3.4 ZD6474 enhances the effect of UV-B in reducing mitochondrial membrane potential ( $\Delta\Psi_m$ )	

5.3.5 ZD6474 enhances the downstream activation of Caspase-3 and Caspase-7 by UV-B radiation	
5.3.6 ZD6474 alters cell regulatory proteins and apoptotic proteins when used in combination with UV-B	
5.3.7 ZD6474 inhibits cell migration when used in combination with UV-B radiation	
5.3.8 ZD6474 inhibits VEGF production and its secretion when used in combination with UV-B radiation	
5.3.9 ZD6474 inhibits VEGF-mediated stimulation of VEGF promoter activity in combination with UV-B	
5.3.10 ZD6474 in combination with UV-B induces cytoskeleton reorganization in breast cancer cells	
<b>5.4 Discussion</b>	127-131
<b>References</b>	132-134
<b>Chapter 6: Preparation and characterization of ZD6474-functionalized gold nanoparticle used for in vitro treatment of breast cancer</b>	135-154
<b>6.1 Introduction</b>	136-137
<b>6.2 Materials and Methods</b>	137-140
6.2.1 Reagents	
6.2.2 Cell Lines	
6.2.3 Preparation	
6.2.4 Characterization	
6.2.5 Drug entrapment	
6.2.6 Zeta Potential ( $\zeta$ )	
6.2.7 Agarose gel electrophoresis	
6.2.8 Cell viability by MTT	
6.2.9 Cell cycle and apoptosis	
6.2.10 Hemocompatibility	
6.2.11 Statistical analysis	
<b>6.3 Results</b>	141-148
6.3.1 Preparation and Characterization of gold nanoparticle (AuNp)	
6.3.2 Efficient entrapment of ZD6474 in AuNp	
6.3.3 ZD6474-AuNp decreases cell viability in breast cancer	
6.3.4 ZD647-AuNp enhances apoptosis in breast cancer	
6.3.5 Hemocompatibility of AuNp.	148-151
<b>6.4 Discussion</b>	152
<b>References</b>	
<b>Chapter 7: Conclusions and further scope</b>	155-161
<b>7.1 Conclusions</b>	155-161
<b>7.2 Scopes and future work</b>	161
<b>Curriculum vitae</b>	
<b>Published papers</b>	